Adjuvant immune checkpoint inhibitors across solid tumors: a meta-analysis of phase II-III randomized trials - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Meta-Analysis of Phase II-III Randomized Trials on Adjuvant Immune Checkpoint Inhibitors in Solid Tumors

  • By

  • Mariam Grazia Polito

  • Luisana Sisca

  • Davide Caruso

  • Antonella Cosimati

  • Carla Adriana Ramirez Reinaga

  • Etien Leka

  • Daniele Santini

  • Gian Paolo Spinelli

  • September 7, 2026

Share

  • 1

    This meta-analysis evaluates the efficacy of adjuvant immune checkpoint inhibitors (ICIs) in patients with solid tumors.

  • 2

    Twenty-one randomized controlled trials involving 17,446 patients were included, yielding 23 treatment comparisons.

  • 3

    Adjuvant ICIs significantly improved disease-free survival (DFS/RFS/PFS) and overall survival (OS) compared to non-ICI controls.

  • 4

    DFS/RFS benefits were noted in melanoma, urothelial carcinoma, renal cell carcinoma, and non-small-cell lung cancer.

  • 5

    Exploratory meta-regression suggested tumor type may influence treatment effects, but results require cautious interpretation.

Original Source(s)

Adjuvant immune checkpoint inhibitors across solid tumors: a meta-analysis of phase II-III randomized trials

  • by Mariam Grazia Polito, Luisana Sisca, Davide Caruso, Antonella Cosimati, Carla Adriana Ramirez Reinaga, Etien Leka, Daniele Santini, Gian Paolo Spinelli

  • September 7, 2026

Related Content

Therapy-induced immunoediting and the evolution of cancer immune escape

The Circadian Skin: Chronobiology as a New Frontier in Dermatological Therapy

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min